{"links":{"feed":"https://www.erudio.com/reports/nrg-gu008-nct04134260/feed.json","html":"https://www.erudio.com/reports/nrg-gu008-nct04134260","json":"https://www.erudio.com/reports/nrg-gu008-nct04134260.json","markdown":"https://www.erudio.com/reports/nrg-gu008-nct04134260.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"nrg-gu008-nct04134260"}},"request":"https://www.erudio.com/contact?report=nrg-gu008-nct04134260"},"offer":{"cited_clinicians":42,"cited_commentary_sources":29,"verified_hcp_statements":304,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":54},"for_sale":true,"one_off_usd":1950,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and a pay_url your own payment client can pay over HTTP 402, with MPP (USDC on Tempo) or x402 (USDC on Base). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"nrg-gu008-nct04134260"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. Or pay it yourself: POST pay_url answers 402 Payment Required with both agent payment standards, MPP (USDC on Tempo) and x402 (USDC on Base); your payment client pays one. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=nrg-gu008-nct04134260","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/nrg-gu008-nct04134260","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"deep","size_line":"Deep · 304 verified statements · 236 from 42 confirmed clinicians","size_rule":"Deep: 301+ verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":3400,"6_months":4900,"12_months":6800},"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-15T21:27:06.074545Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":15,"no_commentary_found":0},"aspects":[{"claim_count":6,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":2,"title":"Primary endpoint: Metastasis-free survival (MFS)"},{"claim_count":8,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":5,"title":"Secondary endpoints"},{"claim_count":14,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":9,"title":"Population and setting"},{"claim_count":17,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":9,"title":"The comparison"},{"claim_count":14,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":6,"title":"Safety and tolerability"},{"claim_count":16,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":10,"title":"Design and conduct"},{"claim_count":42,"coverage":"discussed","id":"A1","source_count":4,"title":"Adjuvant versus early-salvage timing and control-arm interpretation"},{"claim_count":18,"coverage":"discussed","id":"A2","source_count":2,"title":"Systemic addition versus replacement of local treatment"},{"claim_count":21,"coverage":"discussed","id":"A3","source_count":8,"title":"Advanced imaging, stage migration and limits of negative scans"},{"claim_count":34,"coverage":"discussed","id":"A4","source_count":5,"title":"Radiation fields, fractionation, focal substitution and boosts"},{"claim_count":38,"coverage":"discussed","id":"A5","source_count":7,"title":"Patient selection, genomic risk and postoperative work-up"},{"claim_count":14,"coverage":"discussed","id":"A6","source_count":1,"title":"Alternative regimens for PET-detected pelvic nodal persistence or relapse"},{"claim_count":26,"coverage":"discussed","id":"A7","source_count":17,"title":"Enrollment access, imaging costs, referrals and patient information"},{"claim_count":41,"coverage":"discussed","id":"A8","source_count":6,"title":"Duration, evidence transfer and clinically meaningful benefit"},{"claim_count":4,"coverage":"discussed","id":"A9","source_count":1,"title":"Proposed ctDNA-adapted escalation and de-escalation research"}],"counts":{"beyond_population_findings":5,"beyond_population_statements":124,"cited_clinicians":42,"cited_clinicians_by_role":{"physician":9,"physician, Medical oncology":4,"physician, Radiation oncology":20,"physician, Surgical oncology":6,"physician, Urology":3},"cited_physicians":42,"cited_sources":30,"claims_by_expression_type":{"comparison":12,"experience":21,"interpretation":75,"opinion":107,"primary_context":1,"question":17,"restatement":32,"uncertainty":20,"unspecified":19},"claims_by_kind":{"protocol_statement":1,"source_observation":303},"clinician_statements":236,"evidence_units":256,"findings":12,"organisational_accounts":3,"people_cited":58,"people_identity_verified":54,"people_total":59,"screened_sources":61,"verified_claims":304},"findings_index":[{"cited_clinicians":4,"id":"F1","structure":{"claims":19,"claims_by_group":{"comparisons":0,"experience":1,"questions":3,"restated":7,"views":8},"limitations":3,"links":{"context":9,"support":21},"ma_question":true,"named_voices":4,"passages":9,"sources":5,"sources_by_kind":{"commentary":2,"media":2,"registry":1}},"title":"Speakers look to INNOVATE to answer whether node-positive salvage treatment benefits from ARPI intensification","evidence_line":"19 statements from 4 speakers in 5 sources, 2 of them podcasts or videos"},{"cited_clinicians":3,"id":"F2","structure":{"claims":11,"claims_by_group":{"comparisons":2,"experience":1,"questions":3,"restated":2,"views":3},"limitations":2,"links":{"context":0,"support":13},"ma_question":true,"named_voices":3,"passages":9,"sources":3,"sources_by_kind":{"media":3}},"title":"One speaker questions whether INNOVATE's two-year hormonal course is too long","evidence_line":"11 statements from 3 speakers in 3 sources, all podcasts or videos"},{"cited_clinicians":6,"id":"F3","structure":{"claims":9,"claims_by_group":{"comparisons":1,"experience":0,"questions":2,"restated":3,"views":3},"limitations":3,"links":{"context":0,"support":9},"ma_question":true,"named_voices":6,"passages":9,"sources":5,"sources_by_kind":{"commentary":2,"media":2,"registry":1}},"title":"X accounts distinguish detectable-PSA salvage eligibility from the adjuvant-treatment debate","evidence_line":"9 statements from 6 speakers in 5 sources, 2 of them podcasts or videos"},{"cited_clinicians":4,"id":"F4","structure":{"claims":10,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":2,"views":6},"limitations":3,"links":{"context":0,"support":10},"ma_question":true,"named_voices":6,"passages":10,"sources":5,"sources_by_kind":{"commentary":5}},"title":"X accounts challenge the original dual-agent rationale; one trial-linked account explains reconsideration","evidence_line":"10 statements from 6 speakers in 5 sources"},{"cited_clinicians":3,"id":"F5","structure":{"claims":11,"claims_by_group":{"comparisons":0,"experience":3,"questions":2,"restated":5,"views":1},"limitations":3,"links":{"context":1,"support":11},"ma_question":true,"named_voices":3,"passages":12,"sources":2,"sources_by_kind":{"commentary":2}},"title":"X accounts weigh radiotherapy flexibility against postoperative tolerability uncertainty","evidence_line":"11 statements from 3 speakers in 2 sources"},{"cited_clinicians":5,"id":"F6","structure":{"claims":22,"claims_by_group":{"comparisons":0,"experience":3,"questions":0,"restated":6,"views":13},"limitations":3,"links":{"context":3,"support":22},"ma_question":true,"named_voices":5,"passages":20,"sources":14,"sources_by_kind":{"commentary":9,"media":5}},"title":"Speakers see participation as dependent on practical access and referral support","evidence_line":"22 statements from 5 speakers in 14 sources, 5 of them podcasts or videos"},{"cited_clinicians":5,"id":"F10","structure":{"claims":14,"claims_by_group":{"comparisons":0,"experience":1,"questions":0,"restated":1,"views":12},"limitations":3,"links":{"context":5,"support":14},"ma_question":true,"named_voices":8,"passages":13,"sources":1,"sources_by_kind":{"commentary":1}},"title":"X accounts differ on adding an ARSI for PET-detected pelvic nodal persistence or relapse","evidence_line":"14 statements from 8 speakers in 1 source"},{"cited_clinicians":14,"id":"F7","population":"beyond","structure":{"claims":40,"claims_by_group":{"comparisons":1,"experience":5,"questions":3,"restated":2,"views":29},"limitations":3,"links":{"context":4,"support":45},"ma_question":true,"named_voices":20,"passages":35,"sources":4,"sources_by_kind":{"commentary":3,"media":1}},"title":"Speakers disagree on adjuvant treatment versus selective early salvage for postoperative pN1 disease","evidence_line":"40 statements from 20 speakers in 4 sources, 1 of them a podcast or video"},{"cited_clinicians":2,"id":"F8","population":"beyond","structure":{"claims":13,"claims_by_group":{"comparisons":0,"experience":1,"questions":3,"restated":1,"views":8},"limitations":3,"links":{"context":1,"support":14},"ma_question":true,"named_voices":3,"passages":14,"sources":1,"sources_by_kind":{"commentary":1}},"title":"X accounts dispute whether systemic benefit makes pelvic radiation unnecessary","evidence_line":"13 statements from 3 speakers in 1 source"},{"cited_clinicians":12,"id":"F9","population":"beyond","structure":{"claims":25,"claims_by_group":{"comparisons":2,"experience":1,"questions":8,"restated":5,"views":9},"limitations":3,"links":{"context":3,"support":25},"ma_question":true,"named_voices":15,"passages":26,"sources":7,"sources_by_kind":{"commentary":4,"media":3}},"title":"X accounts question whether PSMA-directed focal treatment can substitute for early salvage fields","evidence_line":"25 statements from 15 speakers in 7 sources, 3 of them podcasts or videos"},{"cited_clinicians":5,"id":"F11","population":"beyond","structure":{"claims":48,"claims_by_group":{"comparisons":1,"experience":1,"questions":5,"restated":2,"views":39},"limitations":3,"links":{"context":4,"support":62},"ma_question":true,"named_voices":5,"passages":34,"sources":5,"sources_by_kind":{"commentary":1,"media":4}},"title":"Speakers argue for risk-guided hormone use rather than uniform postoperative intensification","evidence_line":"48 statements from 5 speakers in 5 sources, 4 of them podcasts or videos"},{"cited_clinicians":1,"id":"F12","population":"beyond","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":0,"views":3},"limitations":3,"links":{"context":0,"support":4},"ma_question":true,"named_voices":1,"passages":4,"sources":1,"sources_by_kind":{"commentary":1}},"title":"One X account proposes ctDNA-adapted escalation and de-escalation, while another questions the comparison with PSA","evidence_line":"4 statements from 1 speaker in 1 source"}],"open_question":{"basis":"From finding F1 (19 statements from 4 speakers in 5 sources)","cited_claim_ids":["claim-fe4a3ea383bab0bb5a0d","claim-33a870aee2d4c4052171","claim-a106da50088c555c1d04","claim-1e801a1d8abda3d0e09f","claim-1b7ec6bf414a1eae48b6","claim-ea0c41c2d97d72a3d7e3","claim-e9e8ac473cdd78801e7f","claim-d656c99d6f5ee9f6c740","claim-3810a550c95203a26bd8","claim-86941466e0e16fac8fe6","claim-cfc4e344ca82d936f030","claim-18e87cfca55a944cca8c","claim-9ee945ed6d445176d3c2","claim-927d4846b075d8363c84","claim-ee40500c0d638fd60d4f"],"finding_ids":["F1"],"question":"What do clinicians say they need to see from INNOVATE on metastasis-free survival, quality of life and short- and long-term toxicity before routinely adding apalutamide to salvage radiation and hormone therapy for pathologically node-positive prostate cancer with detectable PSA after prostatectomy?"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"Speakers look to INNOVATE to resolve node-positive intensification"},{"id":"section-2","level":2,"title":"One speaker questions whether the two-year hormonal course is excessive"},{"id":"section-3","level":2,"title":"X accounts distinguish salvage eligibility from adjuvant care"},{"id":"section-4","level":2,"title":"X accounts debate the original dual-agent development rationale"},{"id":"section-5","level":2,"title":"X accounts weigh delivery flexibility against tolerability uncertainty"},{"id":"section-6","level":2,"title":"Speakers connect participation with access and patient support"},{"id":"section-7","level":1,"title":"Beyond the trial population"},{"id":"section-8","level":2,"title":"Speakers disagree on treating pN1 disease before PSA becomes detectable"},{"id":"section-9","level":2,"title":"X accounts separate systemic addition from replacement of radiation"},{"id":"section-10","level":2,"title":"X accounts question PET-based omission, delay and focal boosting"},{"id":"section-11","level":2,"title":"Speakers weigh reasons to add, withhold or defer postoperative systemic treatment"},{"id":"section-12","level":2,"title":"One X account proposes biomarker-adapted research rather than uniform escalation"},{"id":"section-13","level":2,"title":"X accounts differ on ARSI addition and fields in a PET-detected nodal case"},{"id":"section-14","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":1}],"id":"T1","label":"Primary endpoint: Metastasis-free survival (MFS)"},{"findings":[{"id":"F1","shared_claims":1}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":8},{"id":"F4","shared_claims":1},{"id":"F6","shared_claims":2}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":4},{"id":"F3","shared_claims":3},{"id":"F4","shared_claims":7},{"id":"F6","shared_claims":1}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1},{"id":"F5","shared_claims":3}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":3},{"id":"F6","shared_claims":12}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-15T21:27:06.074545Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-16T01:15:13Z","record_hash":"12650baedce613446b8bac57e91b4cedb2e2dd15d74473a96388fa6819031d42","release_hash":"df47c56de794af406b0f820858d846acf1688a069b15348a311111a9339888f8","report_id":"erudio-nct04134260","run_id":"9b444141-eaeb-492e-8cce-d4c98dde546f","schema_version":"5.0","slug":"nrg-gu008-nct04134260","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"Radiation oncologists see NRG-GU008 as a way to close an evidence gap, not a basis for routine ARPI use; one highlights Formula 509’s inconclusive findings. Duration draws differing interpretations: one radiation oncologist tentatively favors shorter ADT because of possible other-cause mortality, whereas another draws on RADICALS-HD to explain the rationale for longer ADT. The mortality concern is not a trial finding; the sources reviewed for this edition describe no benefit or comparative-safety results from the trial.","examples":[{"claim_id":"claim-cfc4e344ca82d936f030","finding_id":"F1","identity_check":"npi_registry","month":"2024-02","region":"US","role":"Radiation oncologist","source_type":"youtube","statement":"encourages enrollment in NRG GU 008 INNOVATE wherever the study is open and awaits its results."},{"claim_id":"claim-1e801a1d8abda3d0e09f","finding_id":"F3","identity_check":"npi_registry","month":"2024-05","region":"US","role":"Radiation oncologist","source_type":"youtube","statement":"asks whether standard hormone therapy should be intensified with an ARPI in the adjuvant setting, identifies INNOVATE as investigating apalutamide added to radiation and hormone therapy, and believes this needs more trial work."}],"meta_description":"61 sources screened · 304 verified statements (236 from clinicians verified by NPI or staff page) from 30 sources · 12 findings. Updated Nov 15, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-16T01:15:13Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":61},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","For 2 recordings, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.","Not yet captured in this edition: a view on tailoring salvage treatment because not every patient needs intensification; a view on clinically actionable recurrence and the factors guiding salvage-treatment decisions; a view on variation in imaging work-up and treatment initiation for recurrence after prostatectomy and radiotherapy; a question about avoiding unnecessary therapy and selecting treatment intensity as advanced imaging changes staging; a view on distinguishing recurrence from actionable progression when assessing clinically meaningful salvage-treatment outcomes; a question about imaging-positive disease prevalence among patients considered for salvage radiotherapy.","1 more clinician view in the sources used in this report is not yet captured as evidence in this edition.","135 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 38 sources about other trials or topics are not included; discussion that uses a name the trial shares with other things, without the trial's condition or setting, may be missing.","The sources reviewed for this edition are not a representative sample of HCP opinion; no prevalence, consensus proportion or independent-clinician count can be inferred.","Discussion that did not use the searched trial names or identifiers may be missing. Coverage of unnamed references and transcription variants is therefore incomplete.","Some media passages cannot be confidently assigned to a named speaker. Their views remain attributed to the discussion or presentation rather than to a roster participant.","Some comments qualifying salvage-radiotherapy toxicity and the distinction between biochemical recurrence and acting on recurrence are not fully represented, limiting completeness on those issues.","No INNOVATE efficacy or comparative-safety readout is described. Other-study findings, personal experience, hypotheses and cure-rate aspirations are not results of INNOVATE.","Full protocol and detailed amendment documentation were unavailable. Historical statements about drugs, radiation modalities, imaging and geographic participation should not be treated as current requirements.","Recruitment messages span several years and include both a completion announcement and a later description of an ongoing study. They do not establish live enrollment status.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","Several important arguments extrapolate from broader salvage, adjuvant, clinically node-positive or intact-prostate populations. Those boundaries limit application to INNOVATE's detectable-PSA postoperative pN-positive population.","Reposts, repeated statements and excerpts from the same presentation do not provide additional independent support."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":1,"regulatory":0,"x_thread":20,"x_video":0,"youtube":9},"by_evidence_role":{"commentary":29,"methods":1},"count":30,"evidence_window":{"end":"2026-10-21","start":"2020-10-16"},"retrieval_snapshot":"2026-11-15T19:20:21.066604Z","timeline":[{"count":1,"week":"2020-W42"},{"count":1,"week":"2021-W06"},{"count":1,"week":"2021-W16"},{"count":1,"week":"2021-W17"},{"count":1,"week":"2021-W22"},{"count":1,"week":"2021-W25"},{"count":1,"week":"2021-W40"},{"count":1,"week":"2021-W41"},{"count":2,"week":"2021-W48"},{"count":1,"week":"2021-W50"},{"count":1,"week":"2022-W27"},{"count":1,"week":"2022-W28"},{"count":2,"week":"2022-W35"},{"count":1,"week":"2022-W40"},{"count":1,"week":"2023-W07"},{"count":1,"week":"2023-W35"},{"count":1,"week":"2023-W50"},{"count":2,"week":"2024-W06"},{"count":1,"week":"2024-W07"},{"count":1,"week":"2024-W08"},{"count":1,"week":"2024-W16"},{"count":2,"week":"2024-W17"},{"count":3,"week":"2024-W19"},{"count":1,"week":"2024-W41"},{"count":1,"week":"2026-W17"},{"count":1,"week":"2026-W43"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT04134260:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT04134260:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:38421243","quote_policy":"short_quote_link_out"},{"id":"openfda:d1cda4f7-cb33-46ea-b9ac-431f6452b1a5:20260702","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ho5otbscl53wyxvkxd5soiyo-3mjfk7wtccv2f","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:03a28b","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:3f4b20","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1193262938267754498:0b1aeed5-b88f-4679-8543-a0eb06e00fb0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1235605674090008576:194210ff-ee20-424c-9a8f-e6ef59df5f30","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1235620192413028353:16c18eb1-519a-46c5-871b-07307aa10b9a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1236328286541746178:4009068a-b213-4b43-8ed7-c648f437334c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1238814576390672384:22930bdb-c03a-4329-a142-2c57912a318f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1301121231375212544:5e716b4c-54d8-442e-a453-35dd5f5f19e1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1317235930533662721:5966b382-5f43-4113-b6e6-afdd8b824a64","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1358943021279150080:a70bcfb6-066b-492f-8cb6-e721d372c49a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1386074496201801730:872ea11d-d20c-4871-9734-38c2a906d8b4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1400612976411938821:11b8057c-d1bf-4ab9-a625-11f5f428fefc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1407665014610223106:7af606e1-b0d0-4a1c-8b06-77d42d5295cc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1408463110088888324:aeea8e9d-f55f-44b1-9c0c-120764b867a4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1446526459879755781:01408051-e008-4123-a7df-403c777e0b78","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1466209802758012934:1ce3e13d-5a9c-4e76-99ea-cd33ffcacfed","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1466661728498769920:d8aa698b-0566-4ace-80d1-620c07641dea","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1469743902789931025:8d7edaca-716a-4a2e-9840-8c1072c49062","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1471225739793993730:eeba5c6e-9eab-4959-af48-b0310212a9ee","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1496509114175954945:7730d02c-1e20-472b-81d8-893bd30d5e0d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1498327627685408771:e758c595-507a-4462-9791-dc7d4e454ec9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1499444983631433736:815f5911-b5bf-4187-8c32-2f32cb39307b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1522569543092256769:f3bb6316-021d-475c-95e7-780802a99142","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1545728226357522432:1d2a27cd-a2dc-457d-a99f-a25870f88639","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1565335913739485185:8e1ff8ce-53c7-409c-a08d-4ad88a51937e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1565415418944184320:06716724-41da-4608-a691-5b3ccb40501e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1576964644513910785:be0132a4-e0b6-4a61-98e1-d118b0d4dbb1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1578122590400364544:16a4044c-7b98-4478-b8a0-9ecf5e17d83f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1625864989255909376:508231f6-3d23-415e-9305-6cb3ae4b5392","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1636804883901710347:5549f7d4-8817-40ef-a7dc-ea811794c60b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1696590788694540573:de4bdbea-9727-4404-9558-f64390813b4f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1725224130910343462:a236b2fa-0499-4083-aff3-c1760702d44c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1735755366019776797:81f2cbab-d0f0-47fe-9a0f-12b9da77564d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1761050785499259212:dec47524-6d53-478e-919f-273afcce1753","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1781379617783226425:40415746-8116-4489-a784-a1954600b042","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1783419181922234602:223d362b-4e9b-47e9-8d6c-50ced52663ca","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1783421125898154171:bf9c3828-c225-4fb3-b060-ef355fe32515","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1783447904193065179:ad61385b-3a33-485d-8220-0e94cb222bc4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1784865097657270688:96919223-6afc-4cc2-841f-e85f7c9f613a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1785800002805395596:77325db5-7c2e-47e9-941a-910349b38cac","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1787525157583454228:5adab1da-7392-4cc3-9424-7f56d778c7a5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1844397639879847990:a41bbef8-8b36-4d36-9954-6ee2612ac687","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1891510419426037915:c00af820-c0fe-48ae-b135-66e750a2e8da","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1891553792048451690:5b8ce2d1-3f90-4687-9bde-50c75f51ebda","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1902745995663835532:bde445f7-99d0-433c-b25a-75a59b6725f0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2043765382834438368:1e589998-6313-408f-98ea-6f005913a143","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2047307071226515768:ceb35372-5a28-4b5f-94f4-5d843479af16","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2049762544093405567:72879e26-3dee-45b3-9fb7-ae3dde14801f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2100933003056685480:a5287bc1-0759-43be-a7d6-aeadf405ac8f","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:3oD2QwEgDYw","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:5aRsPj4xApg","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:J4Xle8pSz1k","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:KI2A3cbaCsg","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:LTDDCdy1Kzo","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:TFoLg4Z_gxc","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:VdPbu0baz-M","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:ccqPZhXeQsw","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:imZ3qClUVUA","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:u_17FktlnKU","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:uppBjPJRjeI","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":0,"other":0,"podcast":2,"publication":0,"registry":0,"regulatory":0,"x_thread":47,"x_video":0,"youtube":11},"by_evidence_role":{"commentary":61},"count":61,"evidence_window":{"end":"2026-10-21","start":"2019-11-09"},"retrieval_snapshot":"2026-11-15T19:20:21.066604Z","timeline":[{"count":1,"week":"2019-W45"},{"count":1,"week":"2019-W46"},{"count":3,"week":"2020-W10"},{"count":1,"week":"2020-W11"},{"count":1,"week":"2020-W36"},{"count":1,"week":"2020-W42"},{"count":1,"week":"2021-W06"},{"count":1,"week":"2021-W16"},{"count":1,"week":"2021-W17"},{"count":1,"week":"2021-W22"},{"count":2,"week":"2021-W25"},{"count":1,"week":"2021-W40"},{"count":1,"week":"2021-W41"},{"count":2,"week":"2021-W48"},{"count":1,"week":"2021-W49"},{"count":1,"week":"2021-W50"},{"count":1,"week":"2022-W01"},{"count":1,"week":"2022-W08"},{"count":2,"week":"2022-W09"},{"count":1,"week":"2022-W18"},{"count":1,"week":"2022-W27"},{"count":1,"week":"2022-W28"},{"count":2,"week":"2022-W35"},{"count":2,"week":"2022-W40"},{"count":1,"week":"2022-W41"},{"count":1,"week":"2022-W49"},{"count":1,"week":"2023-W07"},{"count":1,"week":"2023-W11"},{"count":1,"week":"2023-W35"},{"count":1,"week":"2023-W42"},{"count":1,"week":"2023-W46"},{"count":1,"week":"2023-W50"},{"count":2,"week":"2024-W06"},{"count":1,"week":"2024-W07"},{"count":2,"week":"2024-W08"},{"count":1,"week":"2024-W16"},{"count":5,"week":"2024-W17"},{"count":2,"week":"2024-W18"},{"count":3,"week":"2024-W19"},{"count":2,"week":"2024-W41"},{"count":2,"week":"2025-W08"},{"count":1,"week":"2025-W12"},{"count":1,"week":"2025-W38"},{"count":2,"week":"2026-W16"},{"count":1,"week":"2026-W17"},{"count":1,"week":"2026-W18"},{"count":1,"week":"2026-W28"},{"count":1,"week":"2026-W38"},{"count":1,"week":"2026-W43"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":1,"regulatory":0,"x_thread":175,"x_video":0,"youtube":128}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: apalutamide","status":"unmapped"},{"reason":"Unmapped registry intervention: hormone therapy","status":"unmapped"},{"reason":"Unmapped registry intervention: quality-of-life assessment","status":"unmapped"},{"reason":"Unmapped registry intervention: questionnaire administration","status":"unmapped"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Prostate cancer","slug":"prostate-cancer"},{"reason":"Unmapped registry condition: Stage I Prostate Cancer AJCC v8","status":"unmapped"},{"reason":"Unmapped registry condition: Stage II Prostate Cancer AJCC v8","status":"unmapped"},{"reason":"Unmapped registry condition: Stage III Prostate Cancer AJCC v8","status":"unmapped"},{"reason":"Unmapped registry condition: Stage IVA Prostate Cancer AJCC v8","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"NRG-GU008","aliases":["NRG-GU008","Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial","Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy"],"brief_title":"Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial","collaborators":["National Cancer Institute (NCI)"],"conditions":["Prostate Adenocarcinoma","Stage I Prostate Cancer AJCC v8","Stage II Prostate Cancer AJCC v8","Stage III Prostate Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8"],"display_condition":"node-positive prostate cancer after radical prostatectomy","display_interventions":[["apalutamide"]],"enrollment":{"count":586,"type":"ESTIMATED"},"interventions":[{"name":"Apalutamide","synonyms":["ARN 509","ARN-509","ARN509","Erleada","JNJ 56021927","JNJ-56021927"],"type":"DRUG"},{"name":"Biospecimen Collection","synonyms":["Biological Sample Collection","Biospecimen Collected","Specimen Collection"],"type":"PROCEDURE"},{"name":"Bone Scan","synonyms":["Bone Scintigraphy"],"type":"PROCEDURE"},{"name":"Computed Tomography","synonyms":["CAT","CAT Scan","Computed Axial Tomography","Computerized Axial Tomography","Computerized axial tomography (procedure)","Computerized Tomography","Computerized Tomography (CT) scan","CT","CT Scan","tomography"],"type":"PROCEDURE"},{"name":"Hormone Therapy","synonyms":["Chemotherapy-Hormones/Steroids","Endocrine Therapy","Hormonal","Hormonal Therapy","hormone treatment","Hormones"],"type":"DRUG"},{"name":"Magnetic Resonance Imaging","synonyms":["Magnetic Resonance","Magnetic Resonance Imaging (MRI)","Magnetic resonance imaging (procedure)","Magnetic Resonance Imaging Scan","Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance","MR","MR Imaging","MRI","MRI Scan","MRIs","NMR Imaging","NMRI","Nuclear Magnetic Resonance Imaging","sMRI","Structural MRI"],"type":"PROCEDURE"},{"name":"Positron Emission Tomography","synonyms":["Medical Imaging, Positron Emission Tomography","PET","PET Scan","Positron emission tomography (procedure)","Positron Emission Tomography Scan","Positron-Emission Tomography","PT"],"type":"PROCEDURE"},{"name":"Quality-of-Life Assessment","synonyms":["Quality of Life Assessment"],"type":"OTHER"},{"name":"Questionnaire Administration","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"OTHER"},{"name":"Radiation Therapy","synonyms":["Cancer Radiotherapy","Energy Type","ENERGY_TYPE","Irradiate","Irradiated","Irradiation","Radiation","Radiation Therapy, NOS","Radiotherapeutics","Radiotherapy","RT","Therapy, Radiation"],"type":"RADIATION"}],"nct_id":"NCT04134260","official_title":"Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2026-11-01","type":"ESTIMATED"},"primary_endpoints":[{"description":"Kaplan-Meier curves will be generated and metastasis-free survival compared between the two treatment groups by a logrank test, stratified by prostate specific antigen (PSA) level after prostatectomy (never detectable or rising). Cox regression modeling to assess and adjust for the effects of PSA stratum and other baseline covariates will also be performed. The proportional hazards assumption will be tested using Schoenfeld residuals and graphical methods. Martingale residual plots will be examined to determine the best functional form for incorporating covariates into the model. A competing risks analysis will also be performed with time to distant metastasis or death from prostate cancer as the event of interest and death from other causes as the competing risk. Cumulative incidence curves will be generated along with Fine-Gray's test. Patients alive and metastasis free will be censored as of the time of the last negative examination.","measure":"Metastasis-free survival (MFS)","timeFrame":"From randomization to detection of metastatic disease or death from any cause, assessed up to 7.5 years"}],"registered_date":{"date":"2019-10-22","type":"ACTUAL"},"registry_last_updated":"2026-08-17","registry_url":"https://clinicaltrials.gov/study/NCT04134260","short_name":"NRG-GU008","short_name_basis":"canonical_name","sponsor":"NRG Oncology","start_date":{"date":"2020-04-16","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"NRG-GU008","type":"sponsor_study_id"},{"domain":"CTRP (Clinical Trial Reporting Program)","id":"NCI-2019-06838","type":"registry"},{"id":"U10CA180868","type":"nih"}],"study_type":"INTERVENTIONAL"}}}